795 related articles for article (PubMed ID: 16712874)
1. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
2. Chronic fluvastatin treatment alters vascular contraction by inhibiting the Rho/Rho-kinase pathway.
Kansui Y; Fujii K; Goto K; Oniki H; Iida M
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):673-8. PubMed ID: 16895538
[TBL] [Abstract][Full Text] [Related]
3. Involvement of peptidyl-prolyl isomerase Pin1 in the inhibitory effect of fluvastatin on endothelin-1-induced cardiomyocyte hypertrophy.
Sakai S; Shimojo N; Kimura T; Tajiri K; Maruyama H; Homma S; Kuga K; Mizutani T; Aonuma K; Miyauchi T
Life Sci; 2014 May; 102(2):98-104. PubMed ID: 24657892
[TBL] [Abstract][Full Text] [Related]
4. Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-beta(1)/Smad 7 expression in the spontaneously hypertensive rats.
Zhai Y; Gao X; Wu Q; Peng L; Lin J; Zuo Z
Eur J Pharmacol; 2008 Jun; 587(1-3):196-203. PubMed ID: 18430418
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D2 receptor stimulation inhibits angiotensin II-induced hypertrophy in cultured neonatal rat ventricular myocytes.
Li H; Shi S; Sun YH; Zhao YJ; Li QF; Li HZ; Wang R; Xu CQ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):312-8. PubMed ID: 18986329
[TBL] [Abstract][Full Text] [Related]
6. Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription.
Mascaró C; Ortiz JA; Ramos MM; Haro D; Hegardt FG
Arch Biochem Biophys; 2000 Feb; 374(2):286-92. PubMed ID: 10666309
[TBL] [Abstract][Full Text] [Related]
7. Fluvastatin prevents oxidized low-density lipoprotein-induced injury of renal tubular epithelial cells by inhibiting the phosphatidylinositol 3-kinase/Akt-signaling pathway.
Chu G; Jia R; Yang D
J Nephrol; 2006; 19(3):286-95. PubMed ID: 16874687
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Nakamura H
Cancer Res; 2001 Jun; 61(12):4885-91. PubMed ID: 11406567
[TBL] [Abstract][Full Text] [Related]
9. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy.
Ogata Y; Takahashi M; Takeuchi K; Ueno S; Mano H; Ookawara S; Kobayashi E; Ikeda U; Shimada K
J Cardiovasc Pharmacol; 2002 Dec; 40(6):907-15. PubMed ID: 12451324
[TBL] [Abstract][Full Text] [Related]
10. HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells.
Narumiya H; Sasaki S; Kuwahara N; Irie H; Kusaba T; Kameyama H; Tamagaki K; Hatta T; Takeda K; Matsubara H
Cardiovasc Res; 2004 Nov; 64(2):331-6. PubMed ID: 15485693
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.
Ito T; Ikeda U; Shimpo M; Ohki R; Takahashi M; Yamamoto K; Shimada K
Cardiovasc Drugs Ther; 2002 Mar; 16(2):121-6. PubMed ID: 12090904
[TBL] [Abstract][Full Text] [Related]
12. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
Demyanets S; Kaun C; Pfaffenberger S; Hohensinner PJ; Rega G; Pammer J; Maurer G; Huber K; Wojta J
Biochem Pharmacol; 2006 Apr; 71(9):1324-30. PubMed ID: 16540096
[TBL] [Abstract][Full Text] [Related]
13. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Horiguchi A; Sumitomo M; Asakuma J; Asano T; Asano T; Hayakawa M
Clin Cancer Res; 2004 Dec; 10(24):8648-55. PubMed ID: 15623649
[TBL] [Abstract][Full Text] [Related]
14. Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen-activated protein kinase inactivation in organ-cultured artery.
Sakamoto K; Murata T; Chuma H; Hori M; Ozaki H
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):327-33. PubMed ID: 15591221
[TBL] [Abstract][Full Text] [Related]
15. [Changes of c-fos, c-jun mRNA expressions in cardiomyocyte hypertrophy induced by angiotensin II and effects of tanshinone II A].
Zhou DX; Liang QS; He XX; Zhan CY
Zhongguo Zhong Yao Za Zhi; 2008 Apr; 33(8):936-9. PubMed ID: 18619357
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.
Kang BY; Mehta JL
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):283-91. PubMed ID: 19724024
[TBL] [Abstract][Full Text] [Related]
17. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Oi S; Haneda T; Osaki J; Kashiwagi Y; Nakamura Y; Kawabe J; Kikuchi K
Eur J Pharmacol; 1999 Jul; 376(1-2):139-48. PubMed ID: 10440099
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the RhoA/Rho kinase pathway.
Ye Y; Hu SJ; Li L
FEBS Lett; 2009 Sep; 583(18):2997-3003. PubMed ID: 19716825
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells.
Itoh Y; Kimoto K; Imaizumi M; Nakatsuka K
Exp Eye Res; 2007 Mar; 84(3):464-72. PubMed ID: 17217948
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh.
Choi EY; Chang W; Lim S; Song BW; Cha MJ; Kim HJ; Choi E; Jang Y; Chung N; Hwang KC
Eur J Pharmacol; 2010 Feb; 627(1-3):56-62. PubMed ID: 19883640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
